Showing results (781-790 of 808) with videos related to
Sort By:
Pageof 81
Paleoceanography and Paleoclimatology|October 17, 2022
Episodes of Early Pleistocene West Antarctic Ice Sheet Retreat Recorded by Iceberg Alley SedimentsIan Bailey, Sidney Hemming, Brendan T Reilly, et al.The Lancet. Oncology|April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander M M Eggermont, Christian U Blank, Mario Mandalà, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2020
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 TrialAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.European Journal of Cancer (Oxford, England : 1990)|June 15, 2019
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanomaAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.European Journal of Cancer (Oxford, England : 1990)|February 27, 2022
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver J Kennedy, Michal Kicinski, Sara Valpione, et al.European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver John Kennedy, Michal Kicinski, Sara Valpione, et al.Nature Communications|April 20, 2022
Antiphased dust deposition and productivity in the Antarctic Zone over 1.5 million yearsMichael E Weber, Ian Bailey, Sidney R Hemming, et al.European Journal of Cancer (Oxford, England : 1990)|February 25, 2024
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver John Kennedy, Nina Glassee, Michal Kicinski, et al.The Lancet. Oncology|April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialAndrew Bottomley, Corneel Coens, Justyna Mierzynska, et al.American Journal of Human Genetics|March 26, 2021
Low-coverage sequencing cost-effectively detects known and novel variation in underrepresented populationsAlicia R Martin, Elizabeth G Atkinson, Sinéad B Chapman, et al.Pageof 81